Leadman(SZ:300289) Xin Lang Cai Jing·2026-01-27 02:24Group 1 - The core point of the news is that Lidman experienced a decline of 5.06% in its stock price, reaching 7.31 CNY per share, with a trading volume of 73.24 million CNY and a turnover rate of 1.81%, resulting in a total market capitalization of 3.977 billion CNY [1] - Lidman is based in Beijing Economic and Technological Development Zone and was established on November 5, 1997, with its listing date on February 16, 2012. The company's main business includes in vitro diagnostic reagents (67.84%), diagnostic instruments (14.17%), other services (13.21%), and biochemical raw materials (4.78%) [1] Group 2 - From the perspective of Lidman's top ten circulating shareholders, a fund under Yongying Fund ranks among them. The Medical Device ETF (159883) entered the top ten circulating shareholders in the third quarter, holding 2.0113 million shares, which accounts for 0.37% of the circulating shares. The estimated floating loss today is approximately 784,400 CNY [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 3.677 billion CNY. Year-to-date returns are 9.26%, ranking 1688 out of 5548 in its category, while the one-year return is 14.72%, ranking 3691 out of 4285. Since its inception, it has incurred a loss of 46.69% [2] Group 3 - The fund manager of the Medical Device ETF (159883) is Chu Kefa, who has been in the position for 2 years and 168 days. The total asset scale of the fund is 5.205 billion CNY, with the best fund return during the tenure being 103.17% and the worst being -30.27% [3]